40 Stocks Moving In Wednesday's Mid-Day Session

Loading...
Loading...

Gainers

  • Biofrontera Inc. BFRI shares jumped 109.5% to $5.51 after Roth Capital initiated coverage on the stock with a Buy rating and a $20 price target.
  • Longeveron Inc. LGVN gained 48.1% to $25.50 after tumbling 39% on Tuesday. The company last week announced the FDA granted Rare Pediatric Disease designation for Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome.
  • Ocuphire Pharma, Inc. OCUP jumped 38% to $4.80 after the company announced that the first subjects have been enrolled in the MIRA-3 Phase 3 pivotal trial evaluating Nyxol Eye Drops in the reversal of pharmacologically-induced mydriasis.
  • Better Therapeutics, Inc. BTTX shares gained 29% to $8.32 after Chardan Capital initiated coverage on the stock with a Buy rating and a $17 price target.
  • Bridgeline Digital, Inc. BLIN jumped 23.5% to $3.43.
  • Grom Social Enterprises, Inc. GROM gained 23.5% to $2.78. Grom Social Enterprises disclosed that its newest division, Curiosity Ink Media, unwrapped Santa.com.
  • Benessere Capital Acquisition Corp. BENE jumped 21.3% to $12.34. eCombustible Energy will merge with Benessere Capital Acquisition Corp. in a $805 million deal.
  • Spark Networks SE LOV gained 15% to $3.0699. Spark Networks 10% owner Osmium Diamond Lp acquired a total of 1654197 shares at an average price of $2.51.
  • Local Bounti Corporation LOCL jumped 14.8% to $9.20.
  • BIOLASE, Inc. BIOL rose 14.4% to $0.4810 after Nasdaq granted the company 180-day extension to meet minimum bid price requirement. The company also entered into favorable credit deal.
  • Reviva Pharmaceuticals Holdings, Inc. RVPH gained 12.6% to $3.83. Reviva Pharmaceuticals recently posted a Q3 loss of $0.12 per share.
  • Engine Gaming and Media, Inc. GAME rose 12.5% to $3.5780 after the company reported Q4 2021 and FY21 revenue was higher year over year.
  • Pure Storage, Inc. PSTG rose 10.8% to $30.23 after the company reported better-than-expected Q3 EPS and sales results and issued Q4 and FY22 sales guidance above estimates.
  • Golden Ocean Group Limited GOGL rose 9% to $8.71 after reporting Q3 results.
  • HP Inc. HPQ rose 9% to $35.10 after the company reported better-than-expected results for its fourth quarter and issued strong earnings forecast for the current quarter.
  • Meiwu Technology Company Limited WNW shares rose 6.1% to $3.31.


Check out these big penny stock gainers and losers

Losers

  • Vallon Pharmaceuticals, Inc. VLON fell 34.3% to $4.79 after jumping over 80% on Tuesday.
  • Qualigen Therapeutics, Inc. QLGN shares dipped 30.9% to $1.7699 after jumping around 105% on Tuesday.
  • Pasithea Therapeutics Corp. KTTA declined 30.2% to $3.9100. Pasithea Therapeutics priced its 8.68 million share private placement at $3.50 per share.
  • Nordstrom, Inc. JWN shares fell 28.5% to $22.81 after the company reported worse-than-expected Q3 sales results. Jefferies downgraded Nordstrom from Buy to Hold and lowered the price target from $48 to $30.
  • Petros Pharmaceuticals, Inc. PTPI fell 26.1% to $1.7294 after jumping over 75% on Tuesday.
  • Aptevo Therapeutics Inc. APVO fell 25.4% to $12.70. Aptevo Therapeutics shares climbed 163% on Tuesday after the company announced a clinical update for its Phase 1b Expansion trial evaluating APVO436 in the treatment of AML. Preliminary data observed to date includes one complete remission.
  • Esperion Therapeutics, Inc. ESPR shares fell 23.6% to $7.64 after surging over 40% on Tuesday.
  • The Gap, Inc. GPS fell 21.5% to $18.44 after the company reported worse-than-expected Q3 EPS and sales results and cut FY21 adjusted EPS guidance below estimates.
  • Clarus Therapeutics Holdings, Inc. CRXT shares fell 21.5% to $4.5001. Clarus Therapeutics shares jumped 43% on Tuesday after the company was granted a U.S. Patent titled 'Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same.'
  • iSpecimen Inc. ISPC fell 21% to $10.42. iSpecimen shares jumped over 48% on Tuesday on continued upward momentum after the company announced it has been contracted to support new advanced research on COVID-19 seeking insights on its transmissibility, variants, outcomes, and testing validity among multiple population segments.
  • Outlook Therapeutics, Inc. OTLK fell 20.5% to $1.24 after the company reported a $10 million bought deal offering of common stock.
  • Gracell Biotechnologies Inc. GRCL fell 19.5% to $6.27. Gracell Biotechnologies shares gained 22% on Tuesday after the company reported members of its senior management team intend to use personal funds to buy up to $2 million in company ADSs in the open market over the next 3 months.
  • Anaplan, Inc. PLAN shares fell 18.8% to $42.28 after the company reported Q3 earnings results. Piper Sandler downgraded Anaplan from Overweight to Neutral and lowered the price target from $77 to $48.
  • Kura Oncology, Inc. KURA declined 16% to $13.95 after the company announced the FDA placed the KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML) on a partial clinical hold.
  • Noah Holdings Limited NOAH dropped 15.7% to $37.12 following Q3 results. JP Morgan downgraded Noah Holdings from Overweight to Neutral and announced a $50 price target.
  • MediciNova, Inc. MNOV shares fell 14.7% to $3.7689 after surging 44% on Tuesday.
  • Autodesk, Inc. ADSK shares fell 14.6% to $259.28. Autodesk reported upbeat results for its third quarter, but issued disappointing guidance. Autodesk said it sees Q4 revenue of $1.185 billion to $1.2 billion and non-GAAP earnings of $1.41 to $1.47 per share.
  • Viomi Technology Co., Ltd VIOT slipped 14.2% to $3.50 following Q3 results.
  • NerdWallet, Inc. NRDS dropped 13% to $22.10. The company recently priced its IPO at $18 per share.
  • Nuvation Bio Inc. NUVB fell 12.3% to $8.10.
  • TDCX Inc. TDCX dropped 10.8% to $20.19 following Q3 results.
  • Dillard's, Inc. DDS fell 9.2% to $372.59.
  • Abercrombie & Fitch Co. ANF fell 6.4% to $38.49. Abercrombie & Fitch recently reported third-quarter FY21 sales growth of 10% year-on-year, to $905.16 million, beating the analyst consensus of $896.86 million.
  • Faraday Future Intelligent Electric Inc. FFIE fell 6.4% to $6.15 after the company received anticipated letter from Nasdaq regarding form 10-Q filing.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: NewsPenny StocksSmall CapIntraday UpdateMarketsMoversTrading IdeasMid-Day MoversTop Gainers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...